Compare TYRA & JBLU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | JBLU |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | United States | United States |
| Employees | N/A | 22087 |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2021 | 2002 |
| Metric | TYRA | JBLU |
|---|---|---|
| Price | $33.74 | $4.71 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 11 | 13 |
| Target Price | ★ $47.50 | $4.91 |
| AVG Volume (30 Days) | 749.1K | ★ 23.9M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,062,000,000.00 |
| Revenue This Year | N/A | $12.11 |
| Revenue Next Year | N/A | $6.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.75 | $3.87 |
| 52 Week High | $40.65 | $6.46 |
| Indicator | TYRA | JBLU |
|---|---|---|
| Relative Strength Index (RSI) | 43.61 | 46.93 |
| Support Level | $33.29 | $4.64 |
| Resistance Level | $33.99 | $5.15 |
| Average True Range (ATR) | 1.98 | 0.29 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 30.44 | 37.66 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It served approximately 100 destinations in the United States, the Caribbean and Latin America, Canada, and England. The company currently operates Airbus A321, Airbus A320, Airbus A321neo, and Embraer E190 aircraft types. The company has one operating segment, Air Transportation Services, which provides services in the United States, the Caribbean, Latin America, Canada, and Europe. The majority of revenue is generated from the Domestic & Canada segment.